Drug Approval | November 12, 2021
Sun Pharma to introduce molnupiravir in India
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
The test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of Covid-19
Second interchangeable biosimilar product approved by agency
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
The drug is being developed at lab scale for the first-line of treatment of Covid-19
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
RT-PCR test detects and differentiates SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus
Subscribe To Our Newsletter & Stay Updated
